⌕
Omeros · OMER · Nasdaq
Tenet 31 · Weak
Compare
$16.68−4.63%At closeTenet 31 · Weak
$16.68−0.81 (−4.63%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Omeros (OMER) Stock

Omeros (OMER) closed at $16.68 on Nov 16, 2026; its Tenet Score is 31 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

49 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$16.68
Nov 16, 2026
Market cap
$1.2B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
6.59 – 21.24
low → high · as of close, Nov 16, 2026
Tenet Score
31/100
Weak · 340 Healthcare peers

Industry: Drugs

Omeros Corporation scores 31/100. Weak. Quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 31 is built from 2 of 4 pillars, from 20% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
31/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
14
Health
47
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value & Growth omitted — no data yet.
Value—QualityFHealthDGrowth—MomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
—
Not meaningful: the figure it is divided by is zero or negative.
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
—
Not meaningful: revenue is too small to measure a margin against.
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
2.76
fiscal year to Dec 31, 2025
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Omeros Corporation

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 55 US ETFs · top wrappers by weightSee all ETFs holding OMER →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Omeros in?

Omeros is in the Healthcare sector and the Drugs industry.

What is Omeros' Tenet Score?

Omeros' Tenet Score is 31 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.